CALAVIA Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19

Acalabrutinib

Percentage of Participants Alive and Free of Respiratory Failure at Day 14

Number of Participants With Adverse Events and Serious Adverse Events

Percentage of Participants Alive and Free of Respiratory Failure at Day 28

Percent Change From Baseline in C-reactive Protein.

Percent Change From Baseline in Ferritin

Percent Change From Baseline in Absolute Lymphocyte Count

Overall Survival

Percentage of Participants Alive and Discharged From ICU

Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause

Number of Days Alive and Free of Respiratory Failure

Number of Days With Respiratory Failure

Number of Days Hospitalized

Number of Days in ICU

Number of Days Alive Outside of Hospital

Number of Days Alive Outside of Hospital

Percent Change From Baseline in Oxygenation Index

Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale

Pharmacokinetics of Acalabrutinib

Pharmacokinetics of ACP-5862